Andreas Lutterotti
Andreas Lutterotti
Bestätigte E-Mail-Adresse bei usz.ch
Titel
Zitiert von
Zitiert von
Jahr
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
S Mader, V Gredler, K Schanda, K Rostasy, I Dujmovic, K Pfaller, ...
Journal of neuroinflammation 8 (1), 1-14, 2011
3482011
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2
JD Lünemann, I Jelčić, S Roberts, A Lutterotti, B Tackenberg, R Martin, ...
The Journal of experimental medicine 205 (8), 1763-1773, 2008
2412008
Antigen-specific tolerance by autologous myelin peptide–coupled cells: a phase 1 trial in multiple sclerosis
A Lutterotti, S Yousef, A Sputtek, KH Stürner, JP Stellmann, P Breiden, ...
Science translational medicine 5 (188), 188ra75-188ra75, 2013
2382013
Smoking is a risk factor for early conversion to clinically definite multiple sclerosis
F Di Pauli, M Reindl, R Ehling, F Schautzer, C Gneiss, A Lutterotti, ...
Multiple Sclerosis Journal 14 (8), 1026-1030, 2008
1672008
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica
S Mader, A Lutterotti, F Di Pauli, B Kuenz, K Schanda, F Aboul-Enein, ...
PloS one 5 (5), e10455, 2010
1562010
Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis
B Kuenz, A Lutterotti, R Ehling, C Gneiss, M Haemmerle, C Rainer, ...
PloS one 3 (7), e2559, 2008
1292008
Getting specific: monoclonal antibodies in multiple sclerosis
A Lutterotti, R Martin
The Lancet Neurology 7 (6), 538-547, 2008
1012008
Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders
M Reindl, S Khantane, R Ehling, K Schanda, A Lutterotti, C Brinkhoff, ...
Journal of neuroimmunology 145 (1-2), 139-147, 2003
912003
Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis
R Ehling, A Lutterotti, J Wanschitz, M Khalil, C Gneiss, F Deisenhammer, ...
Multiple Sclerosis Journal 10 (6), 601-606, 2004
762004
Olfactory threshold is impaired in early, active multiple sclerosis
A Lutterotti, M Vedovello, M Reindl, R Ehling, F DiPauli, B Kuenz, ...
Multiple Sclerosis Journal 17 (8), 964-969, 2011
702011
A new paraclinical CSF marker for hypoxia‐like tissue damage in multiple sclerosis lesions
H Lassmann, M Reindl, H Rauschka, J Berger, F Aboul‐Enein, T Berger, ...
Brain 126 (6), 1347-1357, 2003
682003
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity
C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, ...
Multiple Sclerosis Journal 10 (5), 507-510, 2004
662004
Mutations in the gene for toll‐like receptor 4 and multiple sclerosis
M Reindl, A Lutterotti, J Ingram, K Schanda, C Gassner, F Deisenhammer, ...
Tissue Antigens 61 (1), 85-88, 2003
632003
Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis
B Kuenz, A Lutterotti, M Khalil, R Ehling, C Gneiss, F Deisenhammer, ...
Journal of neuroimmunology 167 (1-2), 143-149, 2005
612005
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, ...
Multiple Sclerosis Journal 12 (6), 731-737, 2006
562006
Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people
F Aboul-Enein, T Seifert-Held, S Mader, B Kuenz, A Lutterotti, H Rauschka, ...
PLoS One 8 (11), e79649, 2013
462013
Biological markers for multiple sclerosis
A Lutterotti, T Berger, M Reindl
Current medicinal chemistry 14 (18), 1956-1965, 2007
432007
Persistency of neutralizing antibodies depends on titer and interferon-beta preparation
H Hegen, M Schleiser, C Gneiss, F Di Pauli, R Ehling, B Kuenz, ...
Multiple Sclerosis Journal 18 (5), 610-615, 2012
412012
Antigen-specific tolerization approaches in multiple sclerosis
A Lutterotti, R Martin
Expert opinion on investigational drugs 23 (1), 9-20, 2014
402014
Natalizumab treatment reduces endothelial activity in MS patients
A Millonig, H Hegen, F Di Pauli, R Ehling, C Gneiss, M Hoelzl, B Künz, ...
Journal of neuroimmunology 227 (1-2), 190-194, 2010
372010
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20